Compare Grab Holdings Ltd. (GRAB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Grab Holdings Ltd. vs TG Therapeutics Inc — how do they compare? Grab Holdings Ltd. trades at $3.21 (market cap $12.72B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: Grab Holdings Ltd. is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Grab Holdings Ltd. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Grab Holdings Ltd. for 94 Days and TG Therapeutics Inc for 16 Days on average.
| GRAB | TGTX | |
|---|---|---|
Market Cap | $12.72B | $8.16B |
Volume | 65,352,859 | 1,735,121 |
Sector | Technology | Health |
52-Week High | $6.17 | $59.06 |
52-Week Low | $2.80 | $26.94 |
Typical Hold Time | 94 Days | 16 Days |
Enterprise Value | $8.46B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Grab Holdings (GRAB) trades at $3.195, up 3.73% today, showing strong momentum after recent volatility. The stock demonstrates improving fundamentals with revenue growing from $2.8B in 2024 to $3.37B in 2025 and achieving profitability with $268M net income. Recent Q2 2026 earnings beat expectations with $0.06 EPS versus $0.05 expected, while technical indicators show bearish signals despite neutral oscillators. The company's $1.49B acquisition of Atome Financial positions it for financial services expansion.
Grab presents a compelling turnaround story with accelerating revenue growth and recent profitability. The strong analyst consensus (91.67% buy ratings) and $30M CEO share purchase signal confidence, though technical weakness and competitive pressures in Southeast Asia's ride-hailing market warrant caution. Key catalysts include continued execution on profitability targets and successful integration of Atome acquisition.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Grab Holdings Ltd.
Grab Holdings Limited operates as a holding company. The Company, through its subsidiaries, develops delivery management, mobility, financial services, and enterprise software solutions. Grab Holdings serves customers worldwide.
Read more on GRAB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
